Novartis Consent to Receive Electronic Disclosures
From time to time, Novartis Pharmaceuticals Corporation (“we,” “us,” “our,” or “Company”) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through your user account in various Novartis programs. Please read the information below carefully.
Getting paper copies
At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You may request delivery of such paper copies from us by following the procedure described below.
Withdrawing your consent
If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.
Consequences of changing your mind
If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in communications with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must contact us as described below.
All notices and disclosures will be sent to you electronically
Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you all required notices, disclosures, authorizations, acknowledgments, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.
How to contact Novartis Pharmaceuticals Corporation
You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:
To advise Novartis Pharmaceuticals Corporation of your new email address
To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must call us at 1-888-NOW-NOVA (1-888-669-6682) and state: your previous email address, your new email address. We do not require any other information from you to change your email address.
To request paper copies from Novartis Pharmaceuticals Corporation
To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must call us at 1-888-NOW-NOVA (1-888-669-6682) and state your email address, full name, US postal address, and telephone number.
To withdraw your consent with Novartis Pharmaceuticals Corporation
To inform us that you no longer want to receive future notices and disclosures in electronic format you may:
- Call us at 1-888-NOW-NOVA (1-888-669-6682) and state your email, full name, US postal address, telephone number, and account number. We do not need any other information from you to withdraw consent. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process.
Required hardware and software*:
Windows 2000 or Windows XP
Browsers (for SENDERS):
Internet Explorer 6.0 or above
Browsers (for SIGNERS):
Internet Explorer 6.0, Mozilla FireFox 1.0, NetScape 7.2 (or above)
Access to a valid email account
Enable Security Settings:
- Allow per-session cookies
- Users accessing the internet behind a Proxy Server must enable HTTP 1.1 settings via proxy connection
*These minimum requirements are subject to change. If these requirements change, we will provide you with an email message at the email address we have on file for you at that time, with the revised hardware and software requirements, at which time you will have the right to withdraw your consent.
Acknowledging your access and consent to receive materials electronically
To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure by checking the appropriate box on the enrollment page.
By checking the “I Agree” box on the enrollment page, you confirm that:
- You can access and read this CONSENT TO RECEIVE ELECTRONIC DISCLOSURES document; and
- You can print on paper the disclosure or save or send the disclosure to a place where you can print it, for future reference and access; and
- Until or unless you notify Novartis Pharmaceuticals Corporation as described above, you consent to receive from us exclusively through electronic means all notices, disclosures, authorizations, acknowledgments, and other documents that are required to be provided or made available to you by Novartis Pharmaceuticals Corporation during the course of your relationship with us.